BBOT

424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

10-Q - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitorClinical readouts expected in the second half of 2026 across all three programsCash runway expected to fund operations into 2028 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on May 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in March 2026. The employee received non-qualified stock options to purchase 32,675 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $7.66 per share, the closing price of BBOT's common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the first annive

Canaccord Genuity initiated coverage of BridgeBio Oncology Therapeutics with a rating of Buy and set a new price target of $23.00

424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

EFFECT - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

POS AM - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

DEFA14A - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

DEF 14A - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines BBO-11818 demonstrates robust anti-tumor activity as monotherapy and in combination across KRAS-mutant tumor models Updated Phase 1 clinical data are expected in the second half of 2026 SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today presented new preclinical data for BBO-11818, a selective, orally bioavailable non-covalent inhibitor that

Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development experience and scientific/business acumen to bear as the company's top executive Idan Elmelech, who previously served as Senior Vice President of Strategy & Business Development, will assume the position of Chief Operating Officer overseeing finance & accounting, corporate strategy, operations, and business development Neil Kumar, PhD, who played an integral role in the founding of BBOT as part of BridgeBio Pharma, Inc., has been appointed as Executive Chairman by the Board of Directors to guide t

BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycemia BBO-10203 displays strong in vivo combination effects with HER2 inhibitors tucatinib or trastuzumab in HER2AMP models Updated clinical data are expected in the second half of 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today presented new preclinical data in an oral presentation for BBO-10203, a first-in-class covalent sma

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are expected in the second half of 2026 SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BBO-11818 for the treatment of adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma. "Receiving Fast Track designation from the FDA for B

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on April 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in March 2026. The employee received non-qualified stock options to purchase 32,675 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $8.40 per share, the closing price of BBOT's common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the first an